 | • レポートコード：MRC2304D143 • 出版社/出版日：Transparency Market Research / 2023年1月19日 • レポート形態：英文、PDF、205ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、肺疾患治療の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、疾患種類別（喘息、慢性閉塞性肺疾患、肺がん、その他）分析、薬剤クラス別（コルチコステロイド、気管支拡張薬、ムコリッチ、抗菌薬、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、GSK、AstraZeneca、Boehringer Ingelheim、Novartis、Vertex Pharmaceuticals、F. Hoffman La Roche、Teva Pharmaceuticals、Cipla、Fibrogen、Liminal Biosciences、PharmAkea Therapeutics、IQVIAなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の肺疾患治療市場規模：疾患種類別 - 喘息における市場規模 - 慢性閉塞性肺疾患における市場規模 - 肺がんにおける市場規模 - その他疾患における市場規模 ・世界の肺疾患治療市場規模：薬剤クラス別 - コルチコステロイド の市場規模 - 気管支拡張の市場規模 - ムコリッチの市場規模 - 抗菌薬の市場規模 - その他薬剤クラスの市場規模 ・世界の肺疾患治療市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の肺疾患治療市場規模：地域別 - 北米の肺疾患治療市場規模 - ヨーロッパの肺疾患治療市場規模 - アジア太平洋の肺疾患治療市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Lung Disease Therapeutics Market – Scope of Report
TMR’s report on the global lung disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global lung disease therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung disease therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lung disease therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung disease therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global lung disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung disease therapeutics market.
The report delves into the competitive landscape of the global lung disease therapeutics market. Key players operating in the global lung disease therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global lung disease therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market lung disease therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Disease Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Disease Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Drug Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate Globally With Key Countries
5.4. Regulatory Scenario by Region/Globally
5.5. COVID-19 Impact Analysis
6. Global Lung Disease Therapeutics Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Asthma
6.3.2. Chronic Obstructive Pulmonary Disease (COPD)
6.3.3. Lung Cancer
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Lung Disease Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Corticosteroids
7.3.2. Bronchodilator Medications
7.3.3. Mucolytics
7.3.4. Antimicrobial Medications
7.3.5. Others
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Lung Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Lung Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Disease Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease Type, 2017–2031
10.2.1. Asthma
10.2.2. Chronic Obstructive Pulmonary Disease (COPD)
10.2.3. Lung Cancer
10.2.4. Others
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Corticosteroids
10.3.2. Bronchodilator Medications
10.3.3. Mucolytics
10.3.4. Antimicrobial Medications
10.3.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Lung Disease Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2017–2031
11.2.1. Asthma
11.2.2. Chronic Obstructive Pulmonary Disease (COPD)
11.2.3. Lung Cancer
11.2.4. Others
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Corticosteroids
11.3.2. Bronchodilator Medications
11.3.3. Mucolytics
11.3.4. Antimicrobial Medications
11.3.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Disease Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2017–2031
12.2.1. Asthma
12.2.2. Chronic Obstructive Pulmonary Disease (COPD)
12.2.3. Lung Cancer
12.2.4. Others
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Corticosteroids
12.3.2. Bronchodilator Medications
12.3.3. Mucolytics
12.3.4. Antimicrobial Medications
12.3.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Lung Disease Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2017–2031
13.2.1. Asthma
13.2.2. Chronic Obstructive Pulmonary Disease (COPD)
13.2.3. Lung Cancer
13.2.4. Others
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Corticosteroids
13.3.2. Bronchodilator Medications
13.3.3. Mucolytics
13.3.4. Antimicrobial Medications
13.3.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Disease Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2017–2031
14.2.1. Asthma
14.2.2. Chronic Obstructive Pulmonary Disease (COPD)
14.2.3. Lung Cancer
14.2.4. Others
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Corticosteroids
14.3.2. Bronchodilator Medications
14.3.3. Mucolytics
14.3.4. Antimicrobial Medications
14.3.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. Market Attractiveness Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. GSK
15.3.1.1. Company Overview
15.3.1.2. Disease Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. AstraZeneca
15.3.2.1. Company Overview
15.3.2.2. Disease Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Boehringer Ingelheim
15.3.3.1. Company Overview
15.3.3.2. Disease Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Novartis
15.3.4.1. Company Overview
15.3.4.2. Disease Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Vertex Pharmaceuticals
15.3.5.1. Company Overview
15.3.5.2. Disease Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffman La Roche
15.3.6.1. Company Overview
15.3.6.2. Disease Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Teva Pharmaceuticals
15.3.7.1. Company Overview
15.3.7.2. Disease Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Cipla
15.3.8.1. Company Overview
15.3.8.2. Disease Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Liminal Biosciences
15.3.9.1. Company Overview
15.3.9.2. Disease Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Fibrogen
15.3.10.1. Company Overview
15.3.10.2. Disease Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. PharmAkea Therapeutics
15.3.11.1. Company Overview
15.3.11.2. Disease Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. IQVIA
15.3.12.1. Company Overview
15.3.12.2. Disease Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview